Skip to main content
Midas Edge

Phio Pharmaceuticals Corp.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

PHIO$0.84+4.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

ITEM 6.EXHIBITS

EXHIBIT INDEX

Incorporated by Reference Herein
Exhibit NumberDescriptionFormExhibitDate
3.1Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.Current Report on Form 8-K (File No. 001-36304)Exhibit 3.2November 19, 2018
3.2Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.Current Report on Form 8-K (File No. 001-36304)Exhibit 3.1January 14, 2020
3.3Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.Current Report on Form 8-K (File No. 001-36304)Exhibit 3.1January 25, 2023
3.4Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.Current Report on Form 8-K (File No. 001-36304)Exhibit 3.1July 2, 2024
3.5Certificate of Designation of Series D Preferred Stock, dated November 16, 2022.Current Report on Form 8-K (File No. 001-36304)Exhibit 3.1November 16, 2022
3.6Amended and Restated Bylaws of Phio Pharmaceuticals Corp.Current Report on Form 8-K (File No. 001-36304)Exhibit 3.1May 2, 2022
4.1Form of Placement Agent WarrantCurrent Report on Form 8-K (File No. 001-36304)Exhibit 4.2December 8, 2023
4.2Form of Series C/D WarrantCurrent Report on Form 8-K (File No. 001-36304)Exhibit 4.1July 12, 2024
4.3Form of Placement Agent WarrantCurrent Report on Form 8-K (File No. 001-36304)Exhibit 4.2July 12, 2024
4.4Form of Placement Agent WarrantCurrent Report on Form 8-K (File No. 001-36304)Exhibit 4.2December 20, 2024
4.5Form of Placement Agent WarrantCurrent Report on Form 8-K (File No. 001-36304)Exhibit 4.2December 26, 2024
4.6Form of Placement Agent Warrant.Current Report on Form 8-K (File No. 001-36304)Exhibit 4.2January 14, 2025
4.7Form of Placement Agent Warrant.Current Report on Form 8-K (File No. 001-36304)Exhibit 4.2January 15, 2025
4.8Form of Placement Agent Warrant.Current Report on Form 8-K (File No. 001-36304)Exhibit 4.2January 17, 2025
4.9Form of Series J/K WarrantCurrent Report on Form 8-K (File No. 001-36304)Exhibit 4.1July 30, 2025
4.10Form of Placement Agent WarrantCurrent Report on Form 8-K (File No. 001-36304)Exhibit 4.2July 30, 2025
4.11Form of Series A WarrantCurrent Report on Form 8-K (File No. 001-36304)Exhibit 4.1November 6, 2025
4.12Form of Placement Agent WarrantCurrent Report on Form 8-K (File No. 001-36304)Exhibit 4.2November 13, 2025
10.1Amendment No. 1 to Phio Pharmaceuticals Corp. 2020 Long Term Incentive Plan, as amended and restated.Current Report on Form 8-K (File No. 001-36304)Exhibit 10.1September 28, 2026
31.1Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer. *
31.2Sarbanes-Oxley Act Section 302 Certification of Principal Financial Officer. *
32.1Sarbanes-Oxley Act Section 906 Certification of Principal Executive Officer and Principal Financial Officer. **
101.INSInline XBRL Instance Document.*
101.SCHInline XBRL Taxonomy Extension Schema Document.*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.*
104The cover page for this report, formatted in Inline XBRL (included in Exhibit 101).*
*Filed herewith.
**Furnished herewith and not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section or incorporated by reference into any filing under the Securities Act or the Exchange Act.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.